Multiple cytokine- and multiple cytokine receptor-expressing triple-hit B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma
Authors:
- 1 August 2013
- Vol. 45 (5) , 508-510
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma CellsJournal of Biological Chemistry, 2011
- A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cellsBlood, 2010
- Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic IndexArchivum Immunologiae et Therapiae Experimentalis, 2010
- The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCLBlood, 2009
- Interleukin-6 Overexpression Induces Pulmonary HypertensionCirculation Research, 2009
- BCL2 Is a Downstream Effector of MIZ-1 Essential for Blocking c-MYC-induced ApoptosisJournal of Biological Chemistry, 2007
- Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemiaCancer, 2006
- Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in miceCancer Cell, 2005
- Tumour necrosis factor-α in Barrett's oesophagus: a potential novel mechanism of actionOncogene, 2002
- Promotion of IL8, IL10, TNFα and TNFβ production by EBV infectionLeukemia Research, 1996